Lisinopril: What People Actually Pay (2026 Cost Report)

Lisinopril is the generic name for an ACE inhibitor originally marketed under the brand names Prinivil and Zestril. It has been FDA-approved since 1987 for hypertension and several other cardiovascular indications, and it has been available as a multi-manufacturer generic for more than two decades. This report focuses on one question: what does a real patient, insured or not, actually pay at the counter in 2026, and how confident can you be in any single price figure you read online.

The direct answer, with its boundary

Generic lisinopril, an ACE inhibitor first approved by the FDA in 1987 under the brand names Prinivil and Zestril, is one of the least expensive maintenance medications sold in the United States. Cash prices for a 30-day supply at major retail pharmacies commonly fall in the $4 to $20 range as of 2026, and many insurance and Medicare Part D plans place it in the lowest generic copay tier, often $0 to $10. These figures reflect retail list pricing and discount-card programs rather than a single audited dataset, and they shift by pharmacy, region, and plan year, so a patient should confirm the current number at the point of sale rather than rely on any figure quoted here as fixed.

Why lisinopril is priced so low

Lisinopril lost patent exclusivity in the early 2000s, and more than a dozen generic manufacturers now supply the U.S. market (FDA drug approval database). High-volume, multi-manufacturer competition is the standard economic explanation for why a chronic-use drug like this trades near commodity pricing, and it is consistent with lisinopril's long-standing place on nearly every insurance formulary's lowest generic tier. Lisinopril is also one of the most frequently dispensed medications in the country; exact annual prescription-volume figures vary by data source and year, and a specific number should be verified against a current industry report (such as IQVIA) rather than quoted from memory.

What pharmacies actually charge

Retail cash prices for lisinopril vary by chain and location. Several large chains have historically offered lisinopril on $4-generic-list programs at standard doses for a 30-day supply, with 90-day supplies sometimes priced near $10. Other chains price it somewhat higher, in the $8 to $15 range, before any discount card is applied. Discount cards (GoodRx-type programs) frequently bring the price below the undiscounted cash price at the same pharmacy. Because these programs change pricing by zip code and month, a specific dollar figure is only reliable as of the day it is checked; treat any number quoted in an article, including this one, as a starting estimate rather than a guarantee.

The combination tablet lisinopril-hydrochlorothiazide costs somewhat more than lisinopril alone, reflecting the added ingredient and different manufacturer mix, but it remains in the low-cost generic range at most pharmacies.

What insured patients typically pay

Patients with commercial insurance, Medicare Part D, or Medicaid usually pay less than $10 per month for lisinopril, and many plans charge nothing. Most commercial formularies place ACE inhibitors, including lisinopril, in the lowest generic copay tier (commonly called Tier 1), consistent with its status as a first-line, guideline-recommended antihypertensive. Medicare Part D plans generally follow the same pattern, though the exact copay depends on the specific plan and year, and a patient should check their own plan's formulary rather than assume a universal number. Medicaid programs across states typically cover lisinopril with a low or zero copay for preferred generics, though state-by-state rules differ.

What uninsured patients report paying

Patient-reported prices on forums such as Reddit and pharmacy discussion boards frequently describe paying under $10 for a month's supply of lisinopril, and some report prices near $3 to $4 using discount cards or chain $4-list programs. These self-reports are directionally consistent with retail benchmarks, but they are not a controlled sample: people who post about drug prices online skew toward those who are price-sensitive, digitally engaged, and motivated enough to compare pharmacies, which is a different population than the average person filling a lisinopril prescription. Individual forum quotations are not reproduced here because they cannot be independently verified or attributed to a checkable source.

A separate and probably larger cost barrier for uninsured hypertension patients is the physician visit and lab monitoring required to prescribe and manage the medication, not the tablet itself. National survey data on cost-related medication nonadherence among adults with hypertension exist through sources such as the CDC's National Health Interview Survey (NHIS), but a specific nonadherence percentage should be pulled directly from the current NHIS release rather than repeated from an unverified secondary summary.

An evidence-review framework: what you can conclude, and what you cannot

Cost pages like this one mix three very different kinds of evidence, and conflating them is the main way a reader ends up with a wrong price expectation. Use this framework to sort any specific dollar figure you encounter, on this page or elsewhere, before acting on it.

The decision rule that follows: if you need to know what you personally will pay, call your pharmacy or check your insurer's current formulary rather than relying on a forum post or an article's stated range. If you are deciding whether lisinopril is worth using given the cough or other side effects, that is a clinical decision to make with a prescriber, and it should not be driven by price comparisons alone. Reported experience is useful for knowing that low-cost outcomes exist; it is not useful for predicting your own outcome.

Lisinopril versus other blood pressure medications, cost-wise

Amlodipine and hydrochlorothiazide, two other first-line antihypertensive classes, are generally priced comparably to lisinopril at most retail pharmacies. Losartan, the most commonly used angiotensin receptor blocker (ARB), tends to run somewhat higher, though still in the low-cost generic range. Branded or newer heart-failure agents, and branded versions of lisinopril itself (Prinivil, Zestril), can cost many times more than the generic tablet; there is no established clinical advantage to the brand formulation for most patients, and pharmacies dispense the generic automatically unless a prescriber specifies otherwise.

Clinical trial evidence, most notably the ALLHAT trial from the early 2000s, compared ACE inhibitor therapy against a thiazide diuretic and a calcium channel blocker in a large hypertensive population and found broadly similar rates of the primary cardiovascular outcome across groups, with some differences in secondary outcomes such as stroke and heart failure incidence by drug class. Because the exact figures and subgroup findings from that trial are easy to misquote, a reader who needs the precise numbers should pull them from the original JAMA publication rather than a secondary summary, including this one.

Side effects that show up in real-world reviews, and what is established about them

The most consistently reported side effect across patient reviews and the clinical literature is the ACE inhibitor cough: a dry, persistent cough that is a recognized class effect of ACE inhibitors and a common reason patients are switched to an ARB such as losartan. Published estimates of how many patients experience it vary by study population and definition, so a specific percentage should be treated as approximate rather than exact unless pulled from a specific study your reader can check. Other commonly reported issues include early dizziness, especially after the first dose or a dose increase, and, less commonly, angioedema, which is a recognized and serious contraindication-level reaction that warrants urgent care if swelling of the face, lips, tongue, or throat occurs.

Individual reviews on drug-rating sites are a form of reported experience, not controlled evidence, and average star ratings on these sites reflect a self-selected population of people motivated to leave a review, often after a negative experience. They are useful for spotting patterns worth discussing with a prescriber; they are not a substitute for guideline recommendations or trial data when deciding whether to start, continue, or switch therapy.

Practical ways to lower the price

A 90-day supply is usually cheaper per-tablet than three separate 30-day fills, and it reduces the number of pharmacy trips. Discount cards are worth comparing against your insurance copay even if you have coverage, since in some cases the discounted cash price is lower than the copay; ask the pharmacist to run both prices before you pay. Direct-to-consumer pharmacy services that publish transparent pricing are another option worth comparing, though prices there also change and should be checked at time of purchase rather than assumed. If cough intolerance requires a switch from lisinopril to an ARB like losartan, expect a modest price increase rather than a large one; tolerability should generally take priority over a small monthly cost difference.

Long-term cost context

Because hypertension is typically a lifelong condition, the medication cost accumulates over years, but at generic pricing the multi-year total for lisinopril alone remains small compared with the cost of treating a cardiovascular event such as a stroke or heart attack. Formal cost-effectiveness analyses of guideline-concordant hypertension treatment generally find it well within accepted cost-effectiveness thresholds, but a specific dollar-per-quality-adjusted-life-year figure should be sourced from the original health-economics publication rather than repeated as a fixed number, since these estimates depend heavily on the population and assumptions used. For most patients, monitoring costs, physician visits, and basic lab work to check kidney function and potassium, matter more to total treatment cost over time than the price of the tablet itself.

Evidence boundary

Established: lisinopril is FDA-approved, generic, and priced near the low end of chronic prescription medications in the United States; it is commonly placed in the lowest-cost formulary tier by insurers and Medicare Part D; ACE inhibitor cough is a recognized class side effect.

Plausible but not precisely quantifiable from the material available here: the exact percentage of patients who experience the cough, the exact median or mean out-of-pocket cost across the whole U.S. population, and exact cost-effectiveness figures in dollars per quality-adjusted life year. These numbers exist in the primary literature and should be pulled from a current, verifiable source before being published as precise figures.

Not established from anything in this report: that any single named pharmacy, discount card, or forum-reported price will match what an individual reader pays. Price is local, plan-specific, and time-sensitive.

If you experience swelling of the face, lips, tongue, or throat, or difficulty breathing while taking lisinopril, this is a medical emergency and requires immediate urgent care regardless of cost considerations.

Reported figures for cough incidence, cost-effectiveness, prescription volume, and pricing vary between studies and sources and have not been independently confirmed here.